Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
May 02 2022 - 4:05PM
Business Wire
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that
it will report first quarter financial results on Thursday, May 5,
2022. That same day, Mirum will host a conference call to discuss
the company’s progress and priorities for 2022.
Conference call details: Thursday, May 5, 2022 8:30 a.m. ET/5:30
a.m. PT
Dial-in: U.S./Toll-Free: 844-200-6205 International:
646-904-5544 Passcode: 717854
You may also access the call via webcast by visiting the Events
& Presentations section on Mirum’s website. A replay of this
webcast will be available for 30 days.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to transforming the treatment of rare diseases. Mirum’s
approved medication is LIVMARLI® (maralixibat) oral solution which
is approved in the U.S. for the treatment of cholestatic pruritus
in patients with Alagille syndrome one year of age and older.
Please view the warnings and precautions available in the
Prescribing information or, for more information, visit
LIVMARLI.com.
Mirum’s late-stage pipeline includes two investigational
treatments for debilitating liver diseases affecting children and
adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter
(IBAT) inhibitor, is currently being evaluated in clinical trials
for pediatric liver diseases and includes the MARCH Phase 3 study
for progressive familial intrahepatic cholestasis (PFIC) and the
EMBARK Phase 2b study for patients with biliary atresia. In
addition, Mirum has an expanded access program open across multiple
countries for eligible patients with ALGS and PFIC.
Mirum has submitted a Marketing Authorization Application to the
European Medicines Agency for maralixibat for the treatment of
cholestatic liver disease in patients with Alagille syndrome.
Mirum’s second investigational treatment, volixibat, also an
oral IBAT inhibitor, is being evaluated in three potentially
registrational studies including the OHANA Phase 2b study for
pregnant women with intrahepatic cholestasis of pregnancy, VISTAS
Phase 2b study for adults with primary sclerosing cholangitis, and
the VANTAGE Phase 2b study for primary biliary cholangitis.
Learn more about Mirum by visiting www.mirumpharma.com. Follow
Mirum on Twitter, Facebook, LinkedIn and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005770/en/
Media Contact: Erin Murphy media@mirumpharma.com Investor
Contacts: Ian Clements, Ph.D. ir@mirumpharma.com Sam Martin Argot
Partners ir@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2023 to Apr 2024